Cases That Test Your Skills

Dementia, bizarre creatures, and a white knight to the rescue

Current Psychiatry. 2013 December;12(12):38-40, 45-47

References

1. Wesnes KA, McKeith IG, Ferrara R, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the Cognitive Drug Research computerized assessment system. Dement Geriatr Cogn Disord. 2002; 13(3):183-192.

2. Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson’s disease and dementia with Lewy bodies. Am J Psychiatry. 2007;164(10):1491-1498.

3. McKeith IG, Wesnes KA, Perry E, et al. Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2004;18(1):94-100.

4. Emre M, Tsolaki , Bonuccelli U, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969-977.

5. Aarsland D, Ballard C, Walker Z, et al. Clinical trials of dementia with Lewy bodies and Parkinson’s disease dementia. Curr Neurol Neurosci Rep. 2012;12(5):492-501.

6. Drach LM. Drug treatment of dementia with Lewy bodies and Parkinson’s disease dementia--common features and differences [in German]. Med Monatsschr Pharm. 2011; 34(2):47-52.

7. Frieling H, Hillemacher T, Ziegenbein M, et al. Treating dopamimetic psychosis in Parkinson’s disease: Structured review and meta-analysis. Eur Neuropsychopharmacol. 2007;17(3):165-171.

8. Marti MJ, Tolosa E, de la Cerda A. Dementia in Parkinson’s disease. J Neurol. 2007;254(suppl 5):41-48.

9. French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson’s disease. Lancet. 1999;353(9169):2041-2042.

10. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord. 2000;15(2):201-211.

11. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113-1124.

12. McKeith IG, Ballard CG, Perry RH et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;54(5):1050-1058.

13. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863-1872.

14. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006;9(suppl 3):417-423.

15. Geser F, Wenning GK, Poewe W, et al. How to diagnose dementia with Lewy bodies: state of the art. Mov Disord. 2005;20(suppl 12):S11-20.

16. Latoo J, Jan F. Dementia with Lewy bodies: clinical review. British Journal of Medical Practioners. 2008;1(1):10-14.

17. McKeith I. Dementia with Lewy bodies. Dialogues Clin Neurosci. 2004;6(3):333-341.

18. Litvan I, Bhatia KP, Burn DJ, et al; Movement Disorders Society Scientific Issues Committee. SIC Task Force Appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord. 2003;18(5):467-486.

19. McKeith I, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305(6855):673-678.

20. Clozapine Monitoring Guidelines. 2008. http://www.clozapineregistry.com/resuming_treatment_after_interruption.pdf.ashx. Accessed October 31, 2013.

21. Burke WJ, Pfeiffer RF, McComb RD. Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci. 1998;10(2):227-229.

22. Chacko RC, Hurley RA, Jankovic J. Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosci. 1993;5(2):206-208.

23. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031-2036

24. Mori E, Ikeda M, Kosaka K; Donepezil-DLB Study Investiagors. Donepezil for dementia with Lewy bodies: a randomized, placebo‐controlled trial. Ann Neurol. 2012; 72(1):41-52.

25. Ukai K, Aleksic B, Ishihara R, et al. Efficacy of donepezil for the treatment of visual and multiple sensory hallucinations in dementia with Lewy bodies. Clinical Neuropsychopharmacology and Therapeutics. 2011;2:56-58.

26. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613-618.

27. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003;4(4):281-284.

28. Mathys ML, McCarrell J, Sleeper RB, et al. Visual hallucinations treated with the reinitiation of memantine in a patient with Lewy body dementia. Ann Pharmacother. 2013;47(2):e10.

29. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. 2nd ed. http://psychiatryonline.org/pdfaccess.ashx?ResourceID=243205&PDFSource=6. Accessed November 1, 2013.

30. Mosimann U, McKeith IG. Dementia with lewy bodies—diagnosis and treatment. Swiss Med Wkly. 2003;133:131-142.

31. Baskys A, Davis P Atypical antipsychotic quetiapine in the treatment of the psychosis associated with Lewy body dementia. Neurobiol Aging. 2002;23:S63.

32. Culo S, Mulsant BH, Rosen J, et al. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord. 2010;24(4):306-364.

33. Takahashi S, Mizukami K, Yasuno F, et al. Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics. 2009;9(2):56-61.

34. van der Weide J, Steijns LS, van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics. 2003;13(3):169-172.

SSRIs and other antidepressants have not been shown to improve neuropsychiatric symptoms, and often are poorly tolerated.³²

One study found efficacy with electroconvulsive therapy and transcranial magnetic stimulation in treatment-resistant patients.³³

In addition to these treatments, nonpharmaceutical interventions should be employed from the earliest stages of diagnosis and treatment (Table 2). See the Figure for an algorithm for treating DLB. These include educational and behavioral interventions, social support, psychological interventions, and environmental therapies and modifications.

OUTCOME New friends

The creatures return from time to time, Ms. L reports, but are no longer upsetting because the white knight (a sort of mental deus ex machina) leads the once-terrifying things away. She describes the hallucination as a kind of zoological observation, refers to the creatures that once horrified her as “her friends,” and chuckles as she observes their natural history. This new, far more benign hallucination becomes a mainstay of her symptoms, and she is discharged to the care of her husband and family.

Soon after her discharge, her hallucinations resolved completely, but returned briefly when Ms. L resumed smoking cigarettes because smoking is known to lower clozapine serum levels.³⁴

Bottom Line

Consider a low dosage of a neuroleptic when a patient suffers significant distress and behavioral disturbance related to psychotic symptoms in dementia with Lewy bodies and those problems are not relieved by other agents. Low-dose clozapine is an option for refractory psychotic symptoms or in patients with severe extrapyramidal sensitivity. Start low, and go slow.

Related Resources

Bishnoi RJ, Grossberg GT, Manepalli J. Differentiating Alzheimer’s disease from dementia with Lewy bodies. Current Psychiatry. 2012;11(11):22-27.
McKeith I, Emre M. Management of Parkinson’s disease dementia and dementia with Lewy bodies. In: Emre M, ed. Cognitive impairment and dementia in Parkinson’s disease. Oxford, United Kingdom: Oxford University Press; 2010:245-256.

Drug Brand Names

Aripiprazole • Abilify Mirtazapine • Remeron

Clozapine • Clozaril Olanzapine • Zyprexa

Donepezil • Aricept Quetiapine • Seroquel

Haloperidol • Haldol Risperidone • Risperdal

Memantine • Namenda Rivastigmine • Exelon

Disclosures

The authors report no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products.